Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Medtronic to acquire SPR Therapeutics for $650M, expanding chronic pain treatment with temporary nerve stimulation tech.
MDT
$80.48
+$0.01 +0.01%

Medtronic to acquire SPR Therapeutics for $650M, expanding chronic pain treatment with temporary nerve stimulation tech.

Company Fundamentals
20 May 2026
PRNewsWire
View Source
Bullish
pluang ai news

Medtronic announced its plan to acquire SPR Therapeutics for approximately $650 million in cash, aiming to enhance its neuromodulation portfolio with SPR's temporary peripheral nerve stimulation (PNS) technology. This acquisition will enable Medtronic to offer earlier, minimally invasive treatment options for chronic pain, which affects nearly 50 million adults in the U.S. SPR's FDA-cleared SPRINT® PNS System provides a 60-day temporary therapy without permanent implants, broadening patient access and integrating into existing clinical workflows. The deal is expected to close in the first half of Medtronic's Fiscal Year 2027, pending regulatory approvals.

More News (MDT)

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

Global blood glucose monitoring market to nearly double to $39.4B by 2035 with 8.9% CAGR driven by AI and home care trends

The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App